Circulating Tumor Cells, From Biotech Innovation to Clinical Utility Part A

<p>1. Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer<br>Laura S. Munoz-Arcos, Eleonora Nicolò, Mara S. Serafini, Lorenzo Gerratana, Carolina Reduzzi, and Massimo Cristofanilli<br>2. Can we define breast cancer HER2 status of by liquid biopsy?<br>Serena Di Cosimo, Cinzia De Marco, Marco Silvestri, Adele Busico, Andrea Vingiani, Giancarlo Pruneri, and Vera Cappelletti<br>3. Models to study CTCs and CTC culture methods<br>Cristóbal Fernández-Santiago, Rafael López-López, and Roberto Piñeiro Cid<br>4. Settling the uncertainty about unconventional circulating tumor cells: epithelial-to-mesenchymal transition, cell fusion and trogocytosis<br>Giulia Gallerani, Tania Rossi, Manuela Ferracin, and Massimiliano Bonafè<br>5. Circulating tumor cells in cancer-risk populations as a cancer interception tool<br>María José Serrano, Christian Rolfo, José Expósito-Hernandez, Carmen Garrido-Navas, José Javier Lopez-Hidalgo, and Valeria Denninghoff<br>6. Circulating tumor cells and host immunity: a tricky liaison<br>Elena Muraro and Giulia Brisotto</p>